Answers are grounded in this paper and cite their sources.
Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) that has progressed on endocrine therapy. Metronomic administration may offer a better balance of efficacy and safety than standard regimens, but data from previous trials are scarce.
No takes yet. Share an insight, caveat, or question.
Freyer et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: